We are
Helius
Medical.

Helius is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

The Pioneers of Portable
Neurostimulation
Pushing treatment options to rehabilitate lost function into the future
Solutions Backed
by Science
Dedicating years of research to ensure safety and efficacy
Enhancing the
Human Experience
Empowering individuals with neurological disorders and traumatic brain injury (mmTBI) by increasing their independence and quality of life
Real Patients with
Real Results*
“PoNS Therapy™ enabled me to improve my walking. Some tasks seem easier, which make my daily life better.”
Helius Medical Technologies Logo

We are
Helius
Medical.

Helius is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

Our Origin

Helius’ origin stems from the early 1990s, and the pioneering work in neuroplasticity at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison. This work led to the development of the investigational Portable Neuromodulation Stimulator (PoNS®), that delivers neurostimulation via the tongue, which has been shown in clinical studies to improve the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury.

Helius News

NEWTOWN, Pa. , Oct. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it plans to participate in The

October 18, 2024

-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from CMS for its PoNS Controller Deferred to the Next Cycle -- NEWTOWN, Pa., Oct.

October 14, 2024

-- Achieves primary endpoint showing a linear relationship between adherence to PoNS Therapy ® in Phase 2 and improvement in DGI scores from Phase 1 to end of treatment at week 14 -- -- Confirms the therapeutic benefits of PoNS Therapy for gait deficit improvement in people with MS -- NEWTOWN, Pa.,

September 30, 2024

NEWTOWN, Pa., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective August 14, 2024, its independent directors approved equity awards under Helius’ 2021

August 16, 2024

Careers at Helius Medical

At Helius, you can have a positive impact on the lives of millions of people around the globe who rely on our innovations for their recovery. Helius brings together the world’s best talent to succeed in our ongoing mission. Together, we work passionately to develop and deliver easy-to-use technology for neurological wellness. If you want to join us in our mission, we want to hear from you.